Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.36 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12804024 | 1.00 | ALDH1A1 (0.43) | ALDH1A1HSP90AB1SLC7A5ESR1ESR2 | |
| SCHEMBL30765033 | 1.00 | ALDH1A1 (0.43) | ALDH1A1HSP90AB1SLC7A5ESR1ESR2 | |
| SCHEMBL3967937 | 0.91 | ALDH1A1 (0.47) | ALDH1A1SLC7A5CYP4F2CYP4A11 | |
| SCHEMBL2659518 | 0.91 | ALDH1A1 (0.47) | ALDH1A1SLC7A5CYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL1202263 | 0.89 | ALDH1A1 (0.49) | ALDH1A1SLC7A5CYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL4248195 | 0.89 | ALDH1A1 (0.49) | ALDH1A1SLC7A5CYP4F2CYP4A11 | |
| SCHEMBL15933890 | 0.84 | ALDH1A1 (0.42) | ALDH1A1SLC7A5CYP4F2CYP4A11 | |
| SCHEMBL22944374 | 0.84 | ALDH1A1 (0.42) | ALDH1A1SLC7A5CYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL15873938 | 0.82 | ALDH1A1 (0.44) | ALDH1A1SLC7A5CYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL15873940 | 0.82 | ALDH1A1 (0.44) | ALDH1A1SLC7A5CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107090476-B | Sanglifehrin derivatives and process for preparing the same | 爱博利瓦有限公司 | 2021-09-24 | — | — | CN | disclosed |
| EP-3427737-A1 | SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION | NeuroVive Pharmaceutical AB (SE) | 2019-01-16 | — | — | EP | disclosed |
| EP-2654753-B1 | SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION | NEUROVIVE PHARMACEUTICAL AB (SE) | 2018-10-31 | — | — | EP | disclosed |
| EP-2770977-B1 | NOVEL DOSAGE FORM | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-07-12 | — | — | EP | disclosed |
| EP-2770977-B1 | NOVEL DOSAGE FORM | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-07-12 | — | — | EP | disclosed |
| US-9504728-B2 | Dosage form | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-11-29 | — | — | US | disclosed |
| US-9504728-B2 | Dosage form | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-11-29 | — | — | US | disclosed |
| US-9504728-B2 | Dosage form | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-11-29 | — | — | US | disclosed |
| US-9271977-B2 | Sanglifehrin derivatives and methods for their production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-03-01 | — | — | US | disclosed |
| US-9271977-B2 | Sanglifehrin derivatives and methods for their production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-03-01 | — | — | US | disclosed |
| WO-2013061052-A1 | NOVEL DOSAGE FORM | BIOTICA TECHNOLOGY LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| US-20120251581-A1 | Novel Compound and Methods for its Production | Abliva Ab (SE) | 2012-10-04 | — | — | US | disclosed |
| US-20120251581-A1 | Novel Compound and Methods for its Production | Abliva Ab (SE) | 2012-10-04 | — | — | US | disclosed |
| US-20120251581-A1 | Novel Compound and Methods for its Production | Abliva Ab (SE) | 2012-10-04 | — | — | US | disclosed |
| WO-2012131371-A1 | MACROCYCLIC COMPOUND AND METHODS FOR ITS PRODUCTION | BIOTICA TECHNOLOGY LIMITED (GB) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012131377-A1 | MACROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION | BIOTICA TECHNOLOGY LIMITED (GB) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012131371-A1 | MACROCYCLIC COMPOUND AND METHODS FOR ITS PRODUCTION | BIOTICA TECHNOLOGY LIMITED (GB) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012131377-A1 | MACROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION | BIOTICA TECHNOLOGY LIMITED (GB) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012085553-A1 | SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION | BIOTICA TECHNOLOGY LIMITED (GB) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085553-A1 | SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION | BIOTICA TECHNOLOGY LIMITED (GB) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120251581-A1 | Novel Compound and Methods for its Production | EIF2AK2, HAVCR2, CYP51A1 | ALDH1A1 1700/4885HSP90AB1 1595/4885SLC7A5 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.